Feng Yi-Geng, Chen Lei, Zhou Zhi-Heng
Department of Urology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
Zhonghua Nan Ke Xue. 2013 Nov;19(11):1034-8.
To investigate the clinical efficacy of Shuganyiyang Capsule combined with conventional Western medicine (tamsulosin hydrochloride sustained release tablets + prostat tablets) for the treatment of type III prostatitis complicated by erectile dysfunction (ED).
Eighty patients with type III prostatitis complicated by ED were equally randomized to an experimental and a control group, the former treated with Shuganyiyang Capsule combined with tamsulosin hydrochloride sustained release tablets and prostat tablets, while the latter with tamsulosin hydrochloride and prostat only, both for 8 weeks. Then the prostatitis symptoms, erectile function and psychological conditions of the patients were evaluated using NIH-CPSI, IIEF-5, and hospital anxiety and depression scale (HADA and HADD) respectively. The rates of recovery, excellence, effectiveness and ineffectiveness were calculated.
The scores on NIH-CPSI, IIEF-5, HADA and HADD obtained at 4 and 8 weeks after treatment showed statistically significant differences between the two time points as well as from the baseline (P < 0.01). At 8 weeks, the scores on NIH-CPSI, IIEF-5, HADA and HADD were 6.83 +/- 4.96, 21.03 +/- 2.54, 6.05 +/- 1.62, and 5.35 +/- 3.30 in the experimental group, as compared with 7.55 +/- 4.89, 17.68 +/- 4.15, 6.88 +/- 2.45, and 7.85 +/- 3.77 in the control (P < 0.05). The rate of effectiveness was significantly higher in the experimental than in the control group (90% [36/40] vs 70% [28/40], P < 0.05).
Shuganyiyang Capsule combined with conventional Western medicine, such as alpha blockers and galenica, produces definite effect on chronic prostatitis complicated by ED, improves the psychological conditions of the patient, and enhances the therapeutic efficiency of chronic prostatits.
探讨疏肝益阳胶囊联合传统西药(盐酸坦索罗辛缓释片+普适泰片)治疗Ⅲ型前列腺炎合并勃起功能障碍(ED)的临床疗效。
将80例Ⅲ型前列腺炎合并ED患者随机分为试验组和对照组,每组各40例。试验组采用疏肝益阳胶囊联合盐酸坦索罗辛缓释片及普适泰片治疗,对照组仅采用盐酸坦索罗辛及普适泰片治疗,疗程均为8周。分别采用美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)、国际勃起功能指数-5(IIEF-5)及医院焦虑抑郁量表(HADA和HADD)对患者的前列腺炎症状、勃起功能及心理状况进行评估,并计算痊愈率、显效率、有效率及无效率。
治疗后4周和8周试验组患者的NIH-CPSI、IIEF-5、HADA及HADD评分与治疗前比较,差异均有统计学意义(P<0.01);治疗后8周,试验组NIH-CPSI、IIEF-5、HADA及HADD评分分别为(6.83±4.96)分、(21.03±2.54)分、(6.05±1.62)分、(5.35±3.30)分,对照组分别为(7.55±4.89)分、(17.68±4.15)分、(6.88±2.45)分、(7.85±3.77)分,试验组与对照组比较,差异均有统计学意义(P<0.05)。试验组有效率明显高于对照组(90%[36/40]比70%[28/40],P<0.05)。
疏肝益阳胶囊联合α受体阻滞剂及植物制剂等传统西药治疗慢性前列腺炎合并ED疗效确切,能改善患者心理状况,提高慢性前列腺炎的治疗效果。